{"text_format":"1","workbook":"xlsx","n_sheets":3,"sheets":["1999_00-Deutsch","CF_AR","Cash flow EN"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":6,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1904"}

{"sheet":"1999_00-Deutsch","index":0,"n_rows":68,"n_cols":9,"rows_kept":68,"cut":false,"hidden":true,"merged":[]}
["Asclepion-Meditec AG"]
["Kapitalflussrechnung"]
["für die Geschäftsjahre zum 30. September 2000 und 2001"]
[]
[null,null,null,null,null,null,1.95583]
[null,null,null,null,null,null,"30. September",null,"30. September"]
[null,null,null,null,null,null,2000,null,2001]
[null,null,null,null,null,null,"TDM",null,"TDM"]
[]
[]
["Cash Flow aus laufender Geschäftstätigkeit:"]
[null,"Jahresüberschuss ",null,null,null,null,3827,null,-14865]
[null,"Anpassung zur Überleitung des Jahresüberschusses/Jahresfehlbetrags"]
[null,"zur Nettoveränderung der liquiden Mittel aus laufender Geschäftstätigkeit:"]
[null,null,"Abschreibungen",null,null,null,2273,null,2334]
[null,null,"Verluste /(Gewinne) aus Abgang von Sachanlagevermögen",null,null,null,-72,null,85]
[null,null,"Zahlungsunwirksame Erträge",null,null,null,0,null,{"$f":"-(4418+5400+4271+794)","v":-14883}]
[null,null,"Zuführung zu Wertberichtigungen",null,null,null,0,null,13190]
[null,null,"Auswirkung von Wechselkursänderungen",null,null,null,-1815,null,0]
[null,null,"Anpassung Ertragsteuern für Kosten im Zusammenhang mit dem Börsengang",null,null,null,5291,null,0]
[null,null,"Latente Steuern",null,null,null,-706,null,{"$f":"-4271+505","v":-3766}]
[null,null,"Veränderung bei Vermögensgegenständen und Verbindlichkeiten:"]
[null,null,"Erhöhung der Forderungen an verbundene Unternehmen","(Erhöhung) / Verringerung der Forderungen"]
[null,null,null,null,"und Dritte",null,-23032,null,-3319]
[null,null,"Erhöhung Vorräte","Erhöhung Vorräte",null,null,-1529,null,-8688]
[null,null,"(Erhöhung) / Verringerung der aktiven Rechnungs-","(Erhöhung) / Verringerung der aktiven Rechnungs-"]
[null,null,null,null,"abgrenzung und sonstiger Vermögensgegenstände",null,-1432,null,-4835]
[null,null,"(Erhöhung) / Verringerung aktivierter Börseneinführungskosten","Erhöhung aktivierter Börseneinführungskosten",null,null,500,null,0]
[null,null,"Erhöhung / (Verringerung) der Verbindlichkeiten","Erhöhung / (Verringerung) der Verbindlichkeiten"]
[null,null,null,null,"an verbundene Unternehmen und Dritte",null,1616,null,{"$f":"-523","v":-523}]
[null,null,"Erhöhung / (Verringerung) der Rückstellungen, passiven ","Erhöhung / (Verringerung) der Rückstellungen, passiven "]
[null,null,null,null,"Rechnungsabgrenzungen und sonstigen Verbindlichkeiten",null,3088,null,1311]
[null,null,null,null,"Gesamte Anpassungen",null,{"$f":"SUM(G15:G32)-1","v":-15819},null,{"$f":"SUM(I15:I32)","v":-19094}]
[null,null,null,"    Netto-Kapitalzufluss (-abfluss) aus laufender Geschäftstätigkeit","Netto-Kapitalabfluss aus laufender Geschäftstätigkeit",null,{"$f":"+G12+G33","v":-11992},null,{"$f":"+I12+I33","v":-33959}]
["Cash Flow aus der Investitionstätigkeit:"]
[null,"Erwerb von Sachanlagevermögen",null,null,null,null,-2255,null,-17862]
[null,"Erlöse aus dem Verkauf von Sachanlagevermögen",null,null,null,null,125,null,14]
[null,"Erwerb von Minderheitenbeteiligungen an nahestehenden Unternehmen",null,null,null,null,-3548,null,-1301]
[null,"Gewährung von Darlehen",null,null,null,null,-113,null,-6984]
[null,null,null,null,"Netto-Kapitalabfluss aus Investitionstätigkeit",null,{"$f":"SUM(G36:G39)","v":-5791},null,{"$f":"SUM(I36:I39)","v":-26133}]
["Cash Flow aus Finanzierungstätigkeit:"]
[null,"Einnahmen aus der Ausgabe von Stückaktien",null,null,null,null,113994,null,0]
[null,"Aufnahme kurzfristiger Kredite",null,null,null,null,86,null,3162]
[null,"Rückzahlung kurzfristiger Kredite",null,null,null,null,-29386,null,-86]
[null,"Aufnahme langfristiger Kredite",null,null,null,null,125,null,10500]
[null,"Rückzahlung langfristiger Kredite",null,null,null,null,-1914,null,-90]
[null,"Rückzahlungen unter Leasingverträgen",null,null,null,null,-80,null,-686]
[null,"Erlöse aus Sale/Leaseback Transaktion",null,null,null,null,980,null,2681]
[null,null,null,null,"Netto-Kapitalzufluss aus Finanzierungstätigkeit",null,{"$f":"SUM(G42:G48)","v":83805},null,{"$f":"SUM(I42:I48)","v":15481}]
["Auswirkung von Wechselkursänderungen",null,null,null,null,null,-10,null,23]
["Netto-Erhöhung (Verringerung) der liquiden Mittel",null,null,null,null,null,{"$f":"+G34+G40+G49+G50-1","v":66011},null,{"$f":"+I34+I40+I49+I50","v":-44588}]
["Liquide Mittel am Jahresbeginn",null,null,null,null,null,168,null,66179]
["Liquide Mittel am Jahresende",null,null,null,null,null,{"$f":"+G51+G52","v":66179},null,{"$f":"+I51+I52","v":21591}]
[]
["Ergänzende Angaben zum Cash Flow:"]
[null,"gezahlte Zinsen",null,null,null,null,361.99465188692267,null,850]
[null,"gezahlte Steuern vom Einkommen und Ertrag",null,null,null,null,1012.3579247685126,null,1265]
[]
["Nicht zahlungswirksame Investitions- und Finanzierungstätigkeiten"]
[null,"Umwandlung der Kapitalrücklage in Grundkapital",null,null,null,null,3748.7920729306738,null,0]
[null,"Umwandlung Verbindlichkeiten für deferred shares in Grundkapital",null,null,null,null,199.91512554772143,null,0]
[null,"Umwandlung Verbindlichkeiten für deferred shares in Kapitalrücklage",null,null,null,null,399.83025109544286,null,0]
[null,"Umbuchung von Vorratsvermögen in Sachanlagevermögen",null,null,null,null,161,null,369]
[null,"Umbuchung von Forderungen aus Lieferungen und Leistungen"]
[null,null,"in Finanzanlagen",null,null,null,0,null,6260]
[]
[]
["Auf die nachfolgenden Erläuterungen im Anhang wird verwiesen"]

{"sheet":"CF_AR","index":1,"n_rows":27,"n_cols":8,"rows_kept":27,"cut":false,"hidden":true,"merged":[[0,0,0,7],[1,0,1,7],[2,0,2,7]]}
["Carl Zeiss Meditec AG"]
["selected positions"]
["Consolidated statement of cash flow (US GAAP)"]
[]
[null,null,null,null,null,"1. October 2001 -",null,"1. October 2002 -"]
[null,null,null,null,null,"30. June 2002",null,"30. June 2003"]
[null,null,null,null,null,"Tsd. Euro",null,"Tsd. Euro"]
[]
[]
["Cash flow from operating activities"]
[null,null,"Net income",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,"Loss on disposal of discontinued operations",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,"Depreciation and amortisation",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,"Trade accounts receivable",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,"Inventories",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,"Trade accounts payable",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,"Accrued tax expenses","Erhöhung Vorräte",null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,"Other accrued expenses and liabilities","(Erhöhung) / Verringerung der aktiven Rechnungs-",null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Cash flow from investing activities",null,null,null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Cash flow from financing activities"]
[null,"Proceeds from issuance of short-term debt from related parties",null,null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Increase / (decrease) in liabilities due to Treasury",null,null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"(Increase) / decrease in accounts receivable due to Treasury",null,null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Net increase in cash (compared to Oct 1)",null,null,null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}},null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]

{"sheet":"Cash flow EN","index":2,"n_rows":75,"n_cols":9,"rows_kept":75,"cut":false,"hidden":false,"merged":[[1,0,1,8],[2,0,2,8],[29,2,29,4],[55,2,55,4],[56,2,56,4]]}
[]
["Carl Zeiss Meditec AG"]
["Consolidated statement of cash flows (IFRS) for the period \nfrom 1 Oct 14 to 30 Sep 15"]
[]
[null,null,null,null,null,null,"2014/15",null,"2013/14"]
[null,null,null,null,null,null,"1 Oct 14 to 30 Sep 15",null,"1 Oct 13 to 30 Sep 14"]
[null,null,null,null,null,"Note"]
[null,null,null,null,null,null,"k €",null,"k €"]
[]
["Cash flows from operating activities:",null,null,null,null,""]
[null,null,null,null,null,""]
[null,"Net income",null,null,null,"",65561,null,79157]
[null,null,null,null,null,""]
[null,"Adjustments to reconcile net income to net cash provided by / (used in)",null,null,null,""]
[null,"operating activities",null,null,null,""]
[null,null,null,null,null,""]
[null,null,"Income tax expenses",null,null,"(7)",36159,null,35380]
[null,null,"Result from carve-out of microscopy business of Optronik A.S.",null,null,null,0,null,-146]
[null,null,"Interest income / expenses ",null,null,"(6)",1476,null,1011]
[null,null,"Results from investments accounted for using the equity method",null,null,"(6)",11493,null,0]
[null,null,"Result from other participations",null,null,"(6)",-26,null,-18]
[null,null,"Depreciation and amortisation",null,null,"(11) (12)",19162,null,17953]
[null,null,"Appreciation and write-ups",null,null,"(11)",0,null,-272]
[null,null,"Gains / losses on disposal of fixed assets ",null,null,"",-84,null,1550]
[null,null,"Dividends received",null,null,"",26,null,18]
[null,null,"Interest received",null,null,"",1493,null,1679]
[null,null,"Interest paid",null,null,"",-1433,null,-1327]
[null,null,"Income tax reimbursement",null,null,null,3476,null,3369]
[null,null,"Income taxes paid",null,null,"",-40133,null,-52125]
[null,null,"Other material non-cash expense and income",null,null,"(6)",7401,null,-1327]
[]
[null,"Changes in working capital:",null,null,null,""]
[null,null,null,null,null,""]
[null,null,"Trade receivables",null,null,"(17)",-36255,null,15981]
[null,null,"Inventories",null,null,"(16)",-9890,null,-22086]
[null,null,"Other assets",null,null,"(15) (18) (19)",-7973,null,-2716]
[null,null,"Trade payables",null,null,"",13795,null,-7497]
[null,null,"Provisions and financial liabilities",null,null,"(22) (23) (25)",-11979,null,-2002]
[null,null,"Other liabilities",null,null,"(26)",4475,null,-3477]
[]
[null,"Total adjustments",null,null,null,"",-8817,null,-16052]
[null,"Net cash provided by operating activities",null,null,null,"",56744,null,63105]
[null,null,null,null,null,""]
["Cash flows from investing activities:",null,null,null,null,""]
[null,null,null,null,null,""]
[null,"Investment in property, plant and equipment",null,null,null,"(12)",-9772,null,-11141]
[null,"Investment in intangible assets",null,null,null,"(11)",-7001,null,-6980]
[null,"Proceeds from fixed assets",null,null,null,"",742,null,398]
[null,"Purchase of investments accounted for using the equity method",null,null,null,"(13)",-9240,null,0]
[null,"Payments for loans to investments acc. for using the equity method",null,null,null,"(13)",-7479,null,0]
[null,"Payments for other loans",null,null,null,"(27)",-1356,null,0]
[null,"Proceeds from fixed term deposits",null,null,null,"(33)",110000,null,140000]
[null,"Investments in fixed term deposits",null,null,null,"(33)",-110000,null,-110000]
[null,"Acquisition of IOL/ OVD-business IMEX Clinic S.L., Spain",null,null,null,null,0,null,-1939]
[null,"Acquisition of consolidated companies / businesses, net of cash acquired",null,null,null,"(3)"]
[null,null,"(Optronik A.S., Turkey:",null,null,null,-1067,null,-10800]
[null,null,"Aaren Scientific Inc., USA:)",null,null,null,0,null,-51183]
[null,"Carve-out of microscopy business of Optronik A.S.",null,null,null,null,0,null,2208]
[]
[null,"Net cash used in investing activities",null,null,null,"",-35173,null,-49437]
[null,null,null,null,null,""]
["Cash flows from financing activities:",null,null,null,null,""]
[null,"Proceeds from/(repayment of) short-term debt",null,null,null,"",-929,null,-505]
[null,"Proceeds from/(repayment of) noncurrent financial liabilities",null,null,null,"(24)",-480,null,-262]
[null,"(Increase) / decrease in treasury receivables",null,null,null,"(2u) (33)",-10209,null,30484]
[null,"Increase / (decrease) in treasury payables",null,null,null,"(2u) (33)",27378,null,1163]
[null,"Change of leasing liabilities",null,null,null,"(28)",-2526,null,-1814]
[null,"Dividend payments to shareholders of Carl Zeiss Meditec AG",null,null,null,"(9)",-32524,null,-36589]
[null,null,null,null,null,""]
[null,"Net cash provided by/ (used in) financing activities",null,null,null,"",-19290,null,-7523]
[null,null,null,null,null,""]
["Effect of exchange rate fluctuation on cash and cash equivalents",null,null,null,null,"",33,null,-1704]
["Net increase / (decrease)  in cash and cash equivalents",null,null,null,null,"",2314,null,4441]
["Cash and cash equivalents, beginning of reporting period",null,null,null,null,"(20)",10727,null,6286]
["Cash and cash equivalents, end of reporting period",null,null,null,null,"(20)",13041,null,10727]